Lumiata hires former chairman of Valence Health

Lumiata, a predictive analytics company, has appointed Chris Kryder to its board of directors.

Dr. Kryder has most recently served as chairman of Valence Health, which merged with Evolent Health this year. He was previously CEO of Verisk Health through its initial public offering following the merger of D2Hawkeye with ISO.

"Healthcare's shifting landscape demands highly precise, individualized and real-time analytics. Lumiata offers an exciting and meaningful solution that meets this demand," said Dr. Kryder.

"Their medical AI technology is beginning to provide an end-to-end solution for risk bearers - from frictionless and fast data preparation, to precise, clinically-relevant risk analytics that can coordinate more targeted care interventions, and allocate resources to manage costs. I look forward to working with the Lumiata team and helping them accelerate deployment of their solution."

Lumiata's technology, built by a core team of data scientists, clinicians and experts in care delivery, models human pathophysiology by mapping complex relationships between medical science, literature and patient data. The company's flagship product, the Lumiata Risk Matrix, applies dozens of predictive models to develop precise, holistic and clinically-relevant predictions of a patient's clinical conditions over time, which can then be applied toward multiple use cases in risk and care management.

"We're very excited to add Chris to our board on the heels of our recent financing," said Ash Damle, founder and CEO of Lumiata. "Chris' deep understanding of how risk is managed, combined with his clinical background strengthens both the industry and subject matter expertise we have among our current directors, and brings tremendous value to Lumiata's medical AI offering. Moreover, Chris' willingness to join our board is a strong vote of confidence to our management and staff regarding the next-generation innovation we're bringing to the predictive analytics space."